Alpha Cognition Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ACOG Nasdaq 2830 www.alphacognition.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alpha Cognition Inc.

Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory - Mar 5th, 2025 1:35 pm
Alpha Cognition Inc. (NASDAQ:ACOG) surges 13%; retail investors who own 46% shares profited along with institutions - Feb 20th, 2025 1:11 pm
Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease - Feb 12th, 2025 1:30 pm
Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG) - Jan 30th, 2025 4:05 pm
OTC Markets Group Announces Quarterly Index Performance and Rebalancing - Jan 22nd, 2025 12:00 pm
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL - Jan 14th, 2025 1:30 pm
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China - Jan 8th, 2025 1:30 pm
Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call - Jan 6th, 2025 1:30 pm
Alpha Cognition Announces Partial Exercise of Over-allotment Option - Dec 16th, 2024 7:56 pm
Alpha Cognition Announces Voluntary Delisting from CSE - Dec 12th, 2024 11:41 pm
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury - Dec 11th, 2024 1:30 pm